
Agorest25 mg
Everest Pharmaceuticals Ltd.
Agomelatine is indicated for the following condition: Established/Approved Use Major Depressive Disorder (MDD) in adults - Agomelatine is approved (in regulatory jurisdictions where it is marketed and more.
Agomelatine is indicated for the following condition:
Agomelatine is not approved or recommended for use in children or adolescents, and it is not a first-line treatment for bipolar depression or psychotic depression.
| Step | Dose | Notes |
|---|---|---|
| Starting dose | 25 mg once daily | Taken orally at bedtime |
| If no improvement after 2 weeks | May increase to 50 mg once daily (as two 25 mg tablets) | Taken as a single dose at bedtime |
Tablets should be swallowed whole with a glass of water and may be taken with or without food. Treatment response should be reassessed after approximately 3 months and periodically thereafter to determine the continued need for therapy; a minimum treatment duration of 6 months is generally recommended for a depressive episode. Discontinuation should be guided by a physician.
Not recommended; safety and efficacy in patients under 18 years have not been established.
Agomelatine is contraindicated in patients with hepatic impairment (see Contraindications). No dose adjustment has been established for renal impairment; use with caution and only under close medical supervision in patients with severe renal impairment, as data are limited.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.